source
- FDA, Capricor battle over DMD cell therapy's efficacy at adcommThe FDA and Capricor Therapeutics offered sharply opposed interpretations of clinical data backing the company's potential new cell therapy for the rare and fatal Duchenne muscular dystrophy at an…Endpoints · 2h ago↗ source
- Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectationsBiogen officially began reporting revenue from the $5.6 billion acquisition of Apellis in the second quarter, shaking up analysts’ consensus estimates and leading to a beat.BioSpace · 5h ago↗ source
- Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitorA biotech with a bispecific antibody from China and a little-known San Diego startup with a BTK inhibitor from Gossamer Bio have each signed reverse mergers to take their experimental medicines ont…